This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Learn about effective wealth building actions for this year that can enhance your savings and investment strategies for long-term success.
24,006 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Mortgage rates rose again as Iran-related tensions amplify inflation fears, complicating borrowing for homebuyers and...
When a beloved fantasy IP meets a streaming giant, the financial narrative changes as quickly as a plot twist. This a...
A 19% correction can spark questions about buying gold. This guide breaks down what history says, weighs physical gol...
Broadcom reports AI-related revenue more than doubles in the latest quarter, but the stock trades flat as investors w...
A Middle East conflict could lift oil prices and boost inflation in the United States, prompting fresh debates about ...
The latest CBO outlook warns the OASI trust fund could run dry by 2032 if reforms stall, signaling potential changes ...
Pitney Bowes is navigating a pivot from legacy mailing services to software, data, and commerce solutions. This break...
Palantir just beat earnings, yet its stock fell in after-hours trading as traders priced in slower growth and macro h...
NVIDIA stakes its AI dominance on data center hardware while Palantir expands software driven growth, setting up a hi...
Market pullbacks can wipe out gains, but some AI leaders actually gain momentum as fear rises. Learn how to spot a st...
Opal Fuels is on investors’ radar for 2026. This guide breaks down the earnings landscape, core drivers, and how to e...